On November 10th, 2022, the Food and Drug Administration (FDA) approved Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) and platinum-based chemotherapy for treatment of non-small cell lung cancer where there are no changes in ALK or EGFR. The FDA based their approval on the results of the clinical trial POSEIDON which showed that a high percentage of patients receiving the combination of Imjudo and Imfizni with chemotherapy experienced better outcomes as measured by higher overall survival and progression free survival when compared to those taking chemotherapy and a placebo. Additionally, patients receiving Imjudo, Imfizni and chemotherapy were more likely to respond to treatment.
The new approval gives patients new immunotherapy options.
I have been a Keytruda immunotherapy patient for a little more than two years. I went from Stage IV NSCLC to no significant evidence of disease in six months with absolutely no side effects. Yes, I realize my results were not typical, bordering on extraordinary but I am LIVING proof that immunotherapy works and can work with minimal to no side effects.
I have been first on Keytruda (6 months) then for more than a 1 year now, Atezolizumab (also called Tecentriq).
2021: Keytruda infusion through port: first given with chemotherapy.
It works very well. Tumors shrunk.
In April 2021, keytruda infusion taken alone, I experienced progression.
The immunotherapy drug was stopped. Tumors grown instead of shrinking.
May and June 2021, I went to cryoablation and microwave ablation to destroy metastasis
August 17, 2021: After Keytruda I went on Tecentriq infusion+ Cabozantinib tablets.
The drug works well. Tumors shrunk.
In April 2022, I started to experience oligoprogression.
New tumor appeared.
May 2022: I went to SBRT (stereotactic body radiotherapy) to destroy metastasis.
Continue Tecentriq after SBRT..
In September 2022: second oligoprogression.
One tumor doubled volume, the other was shrinking.
September 2022: SBRT again to destroy tumor.
Continuing Tecentriq after SBRT.
October 2022, last ct scan showed tumors shrinking.
It has been a long journey with immunotherapy. It is not finished.
Since 2019 I have been on 2 different immunotherapeutic infusions (Keytruda and Tecentriq). , I am still alive and doing fine. I have experienced few side effects (mouth sores, hypothyroid). The road is not easy but worse to be taken.
Everyone is different what will work for one person will not work for another.
Hope, courage, faith, strong spiritual believe will make you go forward in your journey to healing and recovery.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
New drug approved for patients with MET mutation. 
Some Social Security Disability Tips for Patients with Lung Cancer
FDA approval for Investigational drug Small Cell Lung Cancer
